[HTML][HTML] Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without …
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - Elsevier
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
[HTML][HTML] Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD
AD Ho, J Schetelig, T Bochtler, M Schaich… - Biology of Blood and …, 2016 - Elsevier
Allogeneic hematopoietic cell transplantation (alloHCT) as a postremission therapy in
patients with FLT3-ITD–positive intermediate-risk acute myeloid leukemia (AML) remains …
patients with FLT3-ITD–positive intermediate-risk acute myeloid leukemia (AML) remains …
Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation
O Beyar-Katz, N Lavi, S Ringelstein-Harlev… - Leukemia & …, 2019 - Taylor & Francis
Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without
significant treatment-related mortality (TRM), is particularly appealing in AML with favorable …
significant treatment-related mortality (TRM), is particularly appealing in AML with favorable …
[HTML][HTML] Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD, NPM1-or biallelicCEBPA mutations
K Heidrich, C Thiede, K Schäfer-Eckart, N Schmitz… - Annals of …, 2017 - Elsevier
Background The value of allogeneic hematopoietic cell transplantation (alloHCT) as
postremission treatment is not well defined for patients with intermediate-risk acute myeloid …
postremission treatment is not well defined for patients with intermediate-risk acute myeloid …
[HTML][HTML] Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
P Niparuck, N Limsuwanachot, S Pukiat… - … Hematology & Oncology, 2019 - Springer
Background Cytogenetic abnormalities and mutated genes indicate the role of consolidation
therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute …
therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute …
Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission
Abstract FLT3-ITD and NPM1 mutation refine prognostic stratification in acute myeloid
leukemia (AML) with intermediate-risk cytogenetics. However, data on their role in patients …
leukemia (AML) with intermediate-risk cytogenetics. However, data on their role in patients …
[HTML][HTML] Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD–positive acute myelogenous leukemia
B Oran, J Cortes, A Beitinjaneh, HC Chen… - Biology of Blood and …, 2016 - Elsevier
The adverse prognosis of internal tandem duplication in the FMS-like tyrosine kinase 3 gene
(s)(FLT3-ITD) in patients with acute myelogenous leukemia (AML) may depend on allelic …
(s)(FLT3-ITD) in patients with acute myelogenous leukemia (AML) may depend on allelic …
[HTML][HTML] Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal …
In patients with acute myeloid leukemia (AML) of intermediate-risk (IR) in first remission
(CR1) with no measurable residual disease (MRD negative), the choice of the best …
(CR1) with no measurable residual disease (MRD negative), the choice of the best …
Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly …
JS Ahn, HJ Kim, YK Kim, SH Jung, DH Yang, JJ Lee… - Annals of …, 2016 - Springer
The prognostic significance of molecular mutations (FLT3-ITD, NPM1, and CEBPA
mutations) was examined in patients with normal-karyotype acute myeloid leukaemia (NK …
mutations) was examined in patients with normal-karyotype acute myeloid leukaemia (NK …
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post …
M Pratcorona, S Brunet, J Nomdedéu… - Blood, The Journal …, 2013 - ashpublications.org
Risk associated to FLT3 internal tandem duplication (FLT3-ITD) in patients with acute
myeloid leukemia (AML) may depend on mutational burden and its interaction with other …
myeloid leukemia (AML) may depend on mutational burden and its interaction with other …